SLS

SELLAS Life Sciences Group, Inc.

Price Chart

Latest Quote

$13.34

+0.13 (+0.98%)

Current Price

Previous Close	$13.21
Open	$13.32
Day High	$13.67
Day Low	$12.94
Volume	7,428,624

Fetched: 2026-09-01T02:00:51

Stock Information

Shares Outstanding	201.95M
Total Debt	$737K
Cash Equivalents	$138.34M
Net Income	$-32.46M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$2.69B
EPS (TTM)	$-0.22
Exchange	NCM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$2.56B
Income	$-32.46M
Book/sh	$0.68
Cash/sh	$0.69
Employees	13

Financial Ratios

Quick Ratio	18.28
Current Ratio	18.83
Debt/Eq	0.54

Returns & Margins

ROA	-23.30%
ROE	-39.63%

Ownership

Insider Ownership	0.92%
Institutional Ownership	36.86%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-133.40
P/B	19.56

Analyst Data

Recommendation	strong_buy
Target Price	$32.50

Technical Indicators

SMA20	$12.96
SMA50	$12.44
SMA200	$6.56
RSI	60.75
ATR	1.3358

Shares Float	201.15M
Short Float	28.03%
Short Ratio	8.90
Volatility	2.49
Rel Volume	1.05

Performance History

Week	-6.91%
Month	+33.27%
Quarter	+47.08%
6 Months	+164.16%
YTD	+206.67%
Year	+594.79%
3 Years	+789.33%
5 Years	+44.84%
10 Years	-99.89%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-08-31	$13.34	7,428,624
2026-08-28	$13.21	9,785,000
2026-08-27	$15.21	12,117,400
2026-08-26	$13.73	4,594,600
2026-08-25	$14.09	8,206,800
2026-08-24	$14.33	8,823,400
2026-08-21	$15.46	15,242,100
2026-08-20	$13.40	7,818,900
2026-08-19	$13.85	9,123,100
2026-08-18	$13.10	4,967,800
2026-08-17	$13.00	5,433,300
2026-08-14	$12.78	4,413,600
2026-08-13	$12.36	5,671,900
2026-08-12	$11.77	7,796,800
2026-08-11	$11.05	4,723,100
2026-08-10	$11.04	5,244,400
2026-08-07	$12.01	5,124,100
2026-08-06	$11.70	3,769,700
2026-08-05	$11.86	5,763,700
2026-08-04	$11.81	5,089,800
2026-08-03	$11.22	6,968,500

About SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

📰 Latest News

Sellas CEO Stergiou Says ‘Rigorous, Unblinded’ Data From Pivotal AML Trial Will 'Speak For Itself' As REGAL Catalyst Nears

Stocktwits • 2026-08-31T14:21:01Z

SLS Stock Rises Overnight: Healthcare Execs Tout AML Drug As ‘Game Changer’ Ahead Of Final Trial Trigger

Stocktwits • 2026-08-31T02:29:41Z

Sellas Life (SLS) Falls 13% as Firm Still Mum on ALM Drug Candidate

Insider Monkey • 2026-08-29T03:16:51Z

SLS, IBRX Eye Fresh Oncology Tailwind As Cathie Wood’s ARK Backs Personalized Cancer-Vaccine Future

Stocktwits • 2026-08-27T07:09:34Z

Sellas Traders See Pancreatic Cancer Race After RVMD’s Drug Approval — But Near-Term Focus Remains On SLS’s Leukemia Pipeline

Stocktwits • 2026-08-26T22:22:04Z

SLS, IBRX Catch The Eye Of A Major US Pension Fund — And Big Clinical Catalysts Are On The Horizon

Stocktwits • 2026-08-26T08:12:24Z

SLS Traders Eye This Important Resistance Zone Ahead Of Key AML Data Readout

Stocktwits • 2026-08-24T16:12:19Z

SLS Stock Charges Ahead As AML Trial Buzz Builds: Report Claims Regal Hit 80th Event — Retail Isn’t Convinced

Stocktwits • 2026-08-24T03:36:55Z

SLS Stock Clocks Three Straight Weeks Of Gains On Cancer Vaccine Spillover, REGAL Trial Data Anticipation

Stocktwits • 2026-08-21T21:19:31Z

Is SELLAS (SLS) Turning Sector Hype Into a Durable Cancer Vaccine Story Despite Ongoing Losses?

Simply Wall St. • 2026-08-21T06:10:48Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$0	$0	$0	$1,000,000
Operating Revenue	$0	$0	$0	$1,000,000
Reconciled Cost Of Revenue	-	-	$0	$100,000
Cost Of Revenue	-	-	$0	$100,000
Expenses
Total Expenses	$28,274,000	$31,513,000	$37,869,000	$32,950,000
Net Non Operating Interest Income Expense	$1,411,000	$632,000	$525,000	$317,000
Operating Expense	$28,274,000	$31,513,000	$37,869,000	$32,850,000
General And Administrative Expense	$12,252,000	$12,417,000	$13,862,000	$12,582,000
Other Income Expense	-	-	$4,000	$-9,668,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-26,863,000	$-30,881,000	$-37,340,000	$-41,301,000
Net Interest Income	$1,411,000	$632,000	$525,000	$317,000
Interest Income	$1,411,000	$632,000	$525,000	$317,000
Normalized Income	$-26,863,000	$-30,881,000	$-37,344,000	$-31,633,000
Net Income From Continuing And Discontinued Operation	$-26,863,000	$-30,881,000	$-37,340,000	$-41,301,000
Total Operating Income As Reported	$-28,274,000	$-31,513,000	$-37,869,000	$-41,950,000
Net Income Common Stockholders	$-26,863,000	$-30,881,000	$-37,340,000	$-41,301,000
Net Income	$-26,863,000	$-30,881,000	$-37,340,000	$-41,301,000
Net Income Including Noncontrolling Interests	$-26,863,000	$-30,881,000	$-37,340,000	$-41,301,000
Net Income Continuous Operations	$-26,863,000	$-30,881,000	$-37,340,000	$-41,301,000
Pretax Income	$-26,863,000	$-30,881,000	$-37,340,000	$-41,301,000
Interest Income Non Operating	$1,411,000	$632,000	$525,000	$317,000
Operating Income	$-28,274,000	$-31,513,000	$-37,869,000	$-31,950,000
Special Income Charges	-	-	$0	$-9,704,000
Gross Profit	-	-	$0	$900,000
Per Share
Diluted EPS	$-0.25	$-0.50	$-1.34	$-2.13
Basic EPS	$-0.25	$-0.50	$-1.34	$-2.13
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-28,274,000	$-31,513,000	$-37,873,000	$-22,282,000
EBITDA (Bullshit earnings)	$-28,274,000	$-31,513,000	$-37,869,000	$-31,950,000
EBIT	$-28,274,000	$-31,513,000	$-37,869,000	$-31,950,000
Diluted Average Shares	$109,051,215	$61,202,412	$27,777,111	$19,395,709
Basic Average Shares	$109,051,215	$61,202,412	$27,777,111	$19,395,709
Diluted NI Availto Com Stockholders	$-26,863,000	$-30,881,000	$-37,340,000	$-41,301,000
Research And Development	$16,022,000	$19,096,000	$24,007,000	$20,268,000
Selling General And Administration	$12,252,000	$12,417,000	$13,862,000	$12,582,000
Other Gand A	$12,252,000	$12,417,000	$13,862,000	$12,582,000
Total Unusual Items	-	-	$4,000	$-9,668,000
Total Unusual Items Excluding Goodwill	-	-	$4,000	$-9,668,000
Restructuring And Mergern Acquisition	-	-	$0	$-296,000
Gain On Sale Of Security	-	-	$4,000	$36,000
Tax Provision	-	-	-	$0
Other Special Charges	-	-	-	$10,000,000
Impairment Of Capital Assets	-	-	-	$0
Otherunder Preferred Stock Dividend	-	-	-	-

Fetched: 2026-08-17

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$68,957,000	$7,551,000	$-9,890,000	$2,937,000
Total Assets	$78,345,000	$19,432,000	$6,219,000	$20,943,000
Total Non Current Assets	$3,134,000	$3,105,000	$3,047,000	$3,187,000
Other Non Current Assets	$257,000	$266,000	$275,000	$399,000
Goodwill And Other Intangible Assets	$1,914,000	$1,914,000	$1,914,000	$1,914,000
Current Assets	$75,211,000	$16,327,000	$3,172,000	$17,756,000
Other Current Assets	$223,000	-	-	$46,000
Restricted Cash	$100,000	$100,000	$100,000	$100,000
Prepaid Assets	$3,095,000	$2,341,000	$542,000	$485,000
Cash Cash Equivalents And Short Term Investments	$71,793,000	$13,886,000	$2,530,000	$17,125,000
Cash And Cash Equivalents	$71,793,000	$13,886,000	$2,530,000	$17,125,000
Non Current Prepaid Assets	-	-	-	$399,000
Receivables	-	-	-	-
Debt
Total Debt	$1,001,000	$1,001,000	$906,000	$945,000
Long Term Debt And Capital Lease Obligation	$457,000	$457,000	$460,000	$573,000
Current Debt And Capital Lease Obligation	$544,000	$544,000	$446,000	$372,000
Liabilities
Total Liabilities Net Minority Interest	$7,474,000	$9,967,000	$14,195,000	$16,092,000
Total Non Current Liabilities Net Minority Interest	$457,000	$457,000	$460,000	$577,000
Current Liabilities	$7,017,000	$9,510,000	$13,735,000	$15,515,000
Other Current Liabilities	$42,000	$42,000	$42,000	-
Payables And Accrued Expenses	$4,678,000	$7,147,000	$11,754,000	$13,704,000
Payables	$2,948,000	$3,500,000	$5,639,000	$8,857,000
Accounts Payable	$2,948,000	$3,500,000	$5,639,000	$3,357,000
Derivative Product Liabilities	-	-	$0	$4,000
Other Payable	-	-	-	$5,500,000
Other Non Current Liabilities	-	-	-	-
Non Current Deferred Liabilities	-	-	-	-
Non Current Deferred Taxes Liabilities	-	-	-	-
Current Deferred Liabilities	-	-	-	-
Equity
Common Stock Equity	$70,871,000	$9,465,000	$-7,976,000	$4,851,000
Total Equity Gross Minority Interest	$70,871,000	$9,465,000	$-7,976,000	$4,851,000
Stockholders Equity	$70,871,000	$9,465,000	$-7,976,000	$4,851,000
Retained Earnings	$-274,988,000	$-248,125,000	$-217,244,000	$-179,904,000
Other
Ordinary Shares Number	$153,103,459	$73,977,459	$32,132,890	$21,005,405
Share Issued	$153,103,459	$73,977,459	$32,132,890	$21,005,405
Tangible Book Value	$68,957,000	$7,551,000	$-9,890,000	$2,937,000
Invested Capital	$70,871,000	$9,465,000	$-7,976,000	$4,851,000
Working Capital	$68,194,000	$6,817,000	$-10,563,000	$2,241,000
Capital Lease Obligations	$1,001,000	$1,001,000	$906,000	$945,000
Total Capitalization	$70,871,000	$9,465,000	$-7,976,000	$4,851,000
Additional Paid In Capital	$345,844,000	$257,583,000	$209,265,000	$184,753,000
Capital Stock	$15,000	$7,000	$3,000	$2,000
Common Stock	$15,000	$7,000	$3,000	$2,000
Long Term Capital Lease Obligation	$457,000	$457,000	$460,000	$573,000
Current Capital Lease Obligation	$544,000	$544,000	$446,000	$372,000
Pensionand Other Post Retirement Benefit Plans Current	$1,753,000	$1,777,000	$1,493,000	$1,439,000
Current Accrued Expenses	$1,730,000	$3,647,000	$6,115,000	$4,847,000
Goodwill	$1,914,000	$1,914,000	$1,914,000	$1,914,000
Net PPE	$963,000	$925,000	$858,000	$874,000
Gross PPE	$963,000	$925,000	$858,000	$874,000
Other Properties	$963,000	$925,000	$858,000	$874,000
Preferred Stock	-	-	$0	$0
Current Deferred Revenue	-	-	-	-

Fetched: 2026-08-17

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-28,389,000	$-35,402,000	$-36,910,000	$-28,309,000
Operating Activities
Operating Cash Flow	$-28,389,000	$-35,402,000	$-31,410,000	$-23,809,000
Cash Flow From Continuing Operating Activities	$-28,389,000	$-35,402,000	$-31,410,000	$-23,809,000
Operating Gains Losses	-	-	$-4,000	$-36,000
Investing Activities
Investing Cash Flow	-	$0	$-5,500,000	$-4,500,000
Cash Flow From Continuing Investing Activities	-	$0	$-5,500,000	$-4,500,000
Capital Expenditure	-	-	$-5,500,000	$-4,500,000
Financing Activities
Issuance Of Capital Stock	$23,051,000	$46,164,000	$22,225,000	$23,994,000
Financing Cash Flow	$86,296,000	$46,758,000	$22,315,000	$24,079,000
Cash Flow From Continuing Financing Activities	$86,296,000	$46,758,000	$22,315,000	$24,079,000
Net Other Financing Charges	$-527,000	$-64,000	$-31,000	-
Net Common Stock Issuance	$23,051,000	$46,164,000	$22,225,000	$23,994,000
Common Stock Issuance	$23,051,000	$46,164,000	$22,225,000	$23,994,000
Other
End Cash Position	$71,893,000	$13,986,000	$2,630,000	$17,225,000
Beginning Cash Position	$13,986,000	$2,630,000	$17,225,000	$21,455,000
Changes In Cash	$57,907,000	$11,356,000	$-14,595,000	$-4,230,000
Proceeds From Stock Option Exercised	$63,772,000	$658,000	$121,000	$85,000
Change In Working Capital	$-4,079,000	$-6,646,000	$3,345,000	$5,641,000
Change In Other Current Liabilities	$-635,000	$-533,000	$-518,000	$-471,000
Change In Payables And Accrued Expense	$-2,476,000	$-4,323,000	$3,750,000	$4,859,000
Change In Accrued Expense	$-1,941,000	$-2,184,000	$1,449,000	$3,646,000
Change In Payable	$-535,000	$-2,139,000	$2,301,000	$1,213,000
Change In Account Payable	$-535,000	$-2,139,000	$2,301,000	$1,213,000
Change In Prepaid Assets	$-968,000	$-1,790,000	$113,000	$1,253,000
Other Non Cash Items	$597,000	$561,000	$495,000	$10,161,000
Stock Based Compensation	$1,956,000	$1,564,000	$2,094,000	$1,726,000
Net Income From Continuing Operations	$-26,863,000	$-30,881,000	$-37,340,000	$-41,301,000
Net Intangibles Purchase And Sale	-	$0	$-5,500,000	$-4,500,000
Purchase Of Intangibles	-	$0	$-5,500,000	$-4,500,000
Gain Loss On Investment Securities	-	-	$-4,000	$-36,000
Change In Receivables	-	-	-	$0
Asset Impairment Charge	-	-	-	$0
Deferred Tax	-	-	-	$0
Deferred Income Tax	-	-	-	$0
Change In Other Working Capital	-	-	-	-

Fetched: 2026-08-17